重组人血管内皮抑素逆转人肺腺癌A549／DDP细胞耐药性研究

Reversal effect of recombinant human Endostatin on cisplatin resistance line A549/DDP human lung adenocarcinoma cells

目的探讨重组人血管内皮抑素（rh-ES）对A549／DDP细胞耐药性的逆转作用。方法采用人肺腺癌细胞株A549及耐药细胞株A549／DDP作为研究对象，以顺铂（DDP）与重组人血管内皮抑素两者联合及单独给药的方式分别作用于人肺腺癌细胞株A549及耐药细胞株A549／DDP，作用时间72h，观察不同给药方式造成的同株细胞之间耐药性的不同及不同株细胞间耐药性的差别，采用四甲基偶氮唑蓝（MTT）检测重组人血管内皮抑素对A549／DDP细胞耐药性的逆转作用。结果DDP对A549细胞半数抑制浓度（IC50）为（0．72±0．05）μg／ml，对A549／DDP的IC50为（11．54±0．64）μg／ml。rh-Es联合DDP对A549／DDP的IC50为（2．0±0．1）μg／ml。逆转倍数（RF）为5．77，相对逆转率（RRR）为88．2％。结论重组人血管内皮抑素能逆转A549／DDP对DDP的耐药性。

Objective To evaluate reverse effect of recombinant human Endostatin on drug-resistance of A549/DDP cells to cisplatin （DDP）. Methods Lung adenocarcinoma cell line 3.549 and its DDP-resistant cell line A549/DDP were treated with DDP and recombinant human Endostatin. Difference in drug resistance was analyzed between different regimens （DDP, Endostatin and combination） and between different cell lines （human lung adenocarcinoma A549 and drug resistant A549/DDP）, after a 72h-treatment in vitro. Recerse effect of recombinant human Endostatin on drug-resistance of A549/DDP to DDP was tested by MTT assay. Results The observed 50% inhibitory concentration （IC50） was （0. 72±0. 05） ug/ml against A549 and （11.54± 0.64）against A549/DDP in DDP, and （2.0±0.1 ）μg/ml against A549/DDP in rh-Endostatin-DDP combination respectively, with a reversal fold （RF） of 5.77 and a relative reversal rate of 88. 2%. Conclusion rh-Endostatin may reverse drug-resistance of A549/DDP cells to DDP.